John Oyler, BeiGene CEO (Paul Yeung/Bloomberg via Getty Images)
April 20, 2023 11:06 AM EDTUpdated 04:36 PM
R&D

BeiGene notch­es win for PD-1 drug in stom­ach can­cers. When will part­ner No­var­tis sub­mit for ap­proval?

Lei Lei Wu

News Reporter

BeiGene an­nounced Thurs­day morn­ing that its im­mune check­point in­hibitor helped pa­tients with cer­tain stom­ach can­cers live longer than chemother­a­py alone. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times